You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • PO.7.155 Study of the comorbidities present in the patients included in the registry of systemic lupus erythematosus of the spanish society of rheumatology (relesser)

Article Text

Article menu

Download PDFPDF

Friday 07 October 2022 from 13:00 to 14:10
PO.7 E- poster session 7: patient views and reported outcomes, registries and cohorts
PO.7.155 Study of the comorbidities present in the patients included in the registry of systemic lupus erythematosus of the spanish society of rheumatology (relesser)
  1. A Lois-Iglesias1,
  2. R Iñigo2,
  3. M Galindo Izquierdo3,
  4. J Calvo-Alén4,
  5. V Balboa-Barreiro1,
  6. C Mouriño5,
  7. A Olivé6,
  8. R Melero5,
  9. A Fernández-Nebro7,
  10. M Andrés8,
  11. C Erausquin2,
  12. E Tomero9,
  13. C Fito10,
  14. E Uriarte11,
  15. M Freire1,
  16. C Montilla12,
  17. A Morasat13,
  18. G Santos-Soler14,
  19. A Boteanu15,
  20. E León16,
  21. J Narvaez17,
  22. V Taboada18,
  23. L Silva1,
  24. O Ibarguengoitia19,
  25. M Fernandez-Castro20,
  26. JA Hernadez-Beirian21,
  27. M Gantes22,
  28. B Hernández-Cruz23,
  29. J Pérez-Venegas24,
  30. A Pecondon25,
  31. N Lozano26,
  32. AP Cacheda27,
  33. G Bonilla28,
  34. V Torrente-Segarra29,
  35. I Castellvi30,
  36. JJ Alegre31,
  37. J Calvet32,
  38. JL Marenco33,
  39. E Raya34,
  40. T Vázquez35,
  41. Q Víctor36,
  42. S Muñoz37,
  43. T Otón38,
  44. J Martínez Barrio39 and
  45. JM Pego-Reigosa5
  1. 1C.H.U.A Coruña ~ A Coruña ~ Spain
  2. 2H.U. Gran. Canaria Dr Negrín ~ Gran Canaria ~ Spain
  3. 3H.U. 12 de Octubre ~ Madrid ~ Spain
  4. 4H.U. Araba ~ Spain
  5. 5HU. Vigo ~ Spain
  6. 6Germans Trias i Pujol ~ Barcelona ~ Spain
  7. 7H.U Málaga ~ Spain
  8. 8C.HU. ALicante ~ Alicante ~ Spain
  9. 9H.U. Princesa ~ Madrid ~ Spain
  10. 10H.U. Navarra ~ Spain
  11. 11H.U. Donosti ~ Spain
  12. 12H.U. Salamanca ~ Spain
  13. 13H.U. Principe de Aturias ~ Alcala de Henares ~ Spain
  14. 14H.U Marina Baixa ~ Alicante ~ Spain
  15. 15H.U. Ramón y Cajal ~ Madrid ~ Spain
  16. 16HU. León ~ Spain
  17. 17H.U. Bellvitge ~ Spain
  18. 18H.U. Valdecilla ~ Santander ~ Spain
  19. 19H.U. Basurto ~ Bilbao ~ Spain
  20. 20H.U. Puerta Hierro ~ Madrid ~ Spain
  21. 21H.Insular Gran Canaria ~ Spain
  22. 22H.U Canarias ~ Spain
  23. 23H.U.Virgen Macarena ~ Sevilla ~ Spain
  24. 24H.U. Jerez ~ Spain
  25. 25H.U.Miguel Servet ~ Zaragoza ~ Spain
  26. 26H.U. Virgen Arrixaca ~ Murcia ~ Spain
  27. 27H. Tenerife ~ Spain
  28. 28H.U. La Paz ~ Madrid ~ Spain
  29. 29CSAPG (Consorci Sanitari Alt Penedès Garraf) ~ Alt Penedes ~ Spain
  30. 30Alt Penedes ~ Spain
  31. 31H.U. Peset ~ Valencia ~ Spain
  32. 32H.U. Parc Taulí ~ Sabadell ~ Spain
  33. 33H.U. Valme ~ Cádiz ~ Spain
  34. 34H.U. San Cecilio ~ Granada ~ Spain
  35. 35H.U. Ferrol ~ Spain
  36. 36H. Monforte ~ Spain
  37. 37H.U. Infanta Sofía ~ San Sebastian de los reyes ~ Spain
  38. 38H.U. Torrejón de Ardoz ~ Spain
  39. 39H.U. Grgorio Marañón ~ Madrid ~ Spain

Abstract

Background The survival of patients with systemic lupus erythematosus (SLE) has increased in recent years, but they have higher morbidity and mortality than the general population.

Purpose To study the prevalence of comorbidities in patients with SLE and its relationship with damage, gender and treatments received.

Methods Cross-sectional multicenter descriptive study of a cohort of adult patients with SLE.

Results We studied 3,656 patients, 90.3% women, mean age (±SD) at diagnosis of 35.2(±14.7) years and duration of SLE of 142.6(±100.8) months. We analyzed 27 comorbidities. 79.73% of the patients presented any, with the maximum accumulated being 14. The most frequent were smoking, dyslipidemia and arterial hypertension. 38.05% of patients accumulated damage. Males accumulated more comorbidities (85.48% vs. 79.1%, p=0.003) and damage (47.03% vs. 37.11%, p<0.001). The first criterion for SLE appeared at a younger age in patients who did not have comorbidities: 27.73(±12.04) years vs. 34.47(±14.76) years; p<0.001. We found that there is a positive correlation between the number of comorbidities and the number of systems with damage (Spearman’s Rho = 0.478, p<0.001). There is a positive correlation between the number of comorbidities and damaged systems with the number of hospitalizations by disease activity (Rho=0.265 and 0.396 respectively, p<0.001 in both contrasts) as well as with the number of serious infections (Rho=0.299 and 0.307 respectively, p <0.001 in both contrasts). We found more patients without comorbidities in those who did not receive glucocorticoids (9.94% vs. 15.48%, p<0.001) and more patients with comorbidities in those who did not receive antimalarials (89.1% vs. 81.78%, p<0.001). There were significant differences in the presence of comorbidities in those treated with cyclophosphamide, mycophenolate, azathioprine or rituximab.

Conclusions A high percentage of patients with SLE have comorbidities. With few exceptions, they are more frequent in males. The onset of SLE was later in patients with more comorbidities. We found variations in comorbidities depending on the treatments received.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/lupus-2022-elm2022.175

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.